Neoepitope load, T cell signatures and PD-L2 as combined biomarker strategy for response to checkpoint inhibition immunotherapy

Immune checkpoint inhibition for the treatment of cancer has provided a breakthrough in oncology, and several new checkpoint inhibition pathways are currently being investigated regarding their potential to provide additional clinical benefit. However, only a fraction of patients respond to such tre...

Descripción completa

Detalles Bibliográficos

Autores principales:	Annie Borch, Anne-Mette Bjerregaard, Vinicius Araujo Barbosa de Lima, Olga Østrup, Christina Westmose Yde, Aron Charles Eklund, Morten Mau-Sørensen, Carolina Barra, Inge Marie Svane, Finn Cilius Nielsen, Samuel A. Funt, Ulrik Lassen, Sine Reker Hadrup
Formato:	Artigo
Lenguaje:	Inglês
Publicado:	Frontiers Media S.A. 2023-03-01
Colección:	Frontiers in Genetics
Materias:	tumor mutational burden neoepitopes T cell signatures immunotherapy immune checkpoint inhibition biomarker
Acceso en línea:	https://www.frontiersin.org/articles/10.3389/fgene.2023.1058605/full
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!